Beta-blocker-induced benefit in heart failure is under intense evaluation.
Several large-scale mortality trials are currently being performed, with CIBIS II evaluating bisoprolol.
The economic impact of beta-blocker therapy in heart failure has not been previously determined.
The present study is a cost-effectiveness evaluation of bisoprolol treatment based on CIBIS I data.
It considers direct costs, that is, the bisoprolol medication cost and the cost of hospitalization related to heart failure and its complications.
Hospitalization costs were calculated from the French system of classification (PMSI), which provides costs according to homogeneous groups of patients (GHM).
The cost difference between bisoprolol and placebo in the entire CIBIS population and the trial duration result from an increase in cost caused by bisoprolol treatment (+2018 Frs/patient) and a decrease in cost related to reduced hospitalization (6349 Frs/patient).
A total savings per patient of about 4330 Frs was produced by bisoprolol.
Cost reduction is still more pronounced in patients not having a history of myocardial infarction.
We conclude that heart failure therapy with bisoprolol lowers medical healthcare costs, mainly due to the reduced rate of hospital admissions for heart failure.
Mots-clés Pascal : Bisoprolol, Antihypertenseur, Bloquant bêta-adrénergique, Analyse coût efficacité, Mortalité, Insuffisance cardiaque, Economie santé, Hospitalisation, Complication, Prévention, Traitement, Chimiothérapie, Homme, In vivo, Placebo, Minimisation coût, Appareil circulatoire pathologie, Cardiopathie
Mots-clés Pascal anglais : Bisoprolol, Antihypertensive agent, Beta blocking agent, Cost efficiency analysis, Mortality, Heart failure, Health economy, Hospitalization, Complication, Prevention, Treatment, Chemotherapy, Human, In vivo, Placebo, Cost minimization, Cardiovascular disease, Heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0013804
Code Inist : 002B02F09. Création : 31/05/1999.